- Home
- CREV vs MBIO Comparison
CREV vs MBIO Comparison
Compare CREV & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CREV
- MBIO
- Stock Information
- Founded
- CREV 2007
- MBIO 2015
- Country
- CREV Ireland
- MBIO United States
- Employees
- CREV N/A
- MBIO N/A
- Industry
- CREV
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- CREV
- MBIO Health Care
- Exchange
- CREV Nasdaq
- MBIO Nasdaq
- Market Cap
- CREV 7.2M
- MBIO 7.3M
- IPO Year
- CREV N/A
- MBIO N/A
- Fundamental
- Price
- CREV $2.73
- MBIO $1.44
- Analyst Decision
- CREV Strong Buy
- MBIO Strong Buy
- Analyst Count
- CREV 1
- MBIO 1
- Target Price
- CREV $39.00
- MBIO $100.00
- AVG Volume (30 Days)
- CREV 14.2K
- MBIO 66.3K
- Earning Date
- CREV 01-01-0001
- MBIO 05-14-2025
- Dividend Yield
- CREV N/A
- MBIO N/A
- EPS Growth
- CREV N/A
- MBIO N/A
- EPS
- CREV N/A
- MBIO N/A
- Revenue
- CREV $39,261,077.00
- MBIO N/A
- Revenue This Year
- CREV $40.76
- MBIO N/A
- Revenue Next Year
- CREV $86.18
- MBIO N/A
- P/E Ratio
- CREV N/A
- MBIO N/A
- Revenue Growth
- CREV 41.52
- MBIO N/A
- 52 Week Low
- CREV $2.00
- MBIO $1.20
- 52 Week High
- CREV $17.15
- MBIO $65.00
- Technical
- Relative Strength Index (RSI)
- CREV 39.84
- MBIO 33.40
- Support Level
- CREV $2.64
- MBIO $1.20
- Resistance Level
- CREV $3.31
- MBIO $1.51
- Average True Range (ATR)
- CREV 0.28
- MBIO 0.11
- MACD
- CREV 0.02
- MBIO 0.11
- Stochastic Oscillator
- CREV 11.11
- MBIO 77.42
About CREV Carbon Revolution Public Limited
Carbon Revolution PLC is an Australian-based technology company manufacturing carbon fiber wheels. It is an OEM supplier and a world-wide manufacturer of lightweight technology carbon fibre wheels to the automotive industry. The Company supplies wheels to OEMs across the globe for luxury and high-performance vehicles and SUVs, and is developing wheels for electric vehicles under contract for its OEM customers. The company generates maximum revenue Internationally.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.